The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Communicable Diseases Drugs Market Research Report 2024
Synopsis
In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global Communicable Diseases Drugs market was valued at US$ 28160 million in 2023 and is anticipated to reach US$ 68580 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
This report aims to provide a comprehensive presentation of the global market for Communicable Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Communicable Diseases Drugs.
Report Scope
The Communicable Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Communicable Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Communicable Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J & J
Teva
AbbVie
Bausch Health
Abbott
Sanofi
Sun Pharma
Endo
Apotex
Amneal Pharma
Torrent Pharma
Segment by Type
HIV
Influenza
TB
Malaria
Hepatitis
HPV
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Communicable Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global Communicable Diseases Drugs market was valued at US$ 28160 million in 2023 and is anticipated to reach US$ 68580 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
This report aims to provide a comprehensive presentation of the global market for Communicable Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Communicable Diseases Drugs.
Report Scope
The Communicable Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Communicable Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Communicable Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J & J
Teva
AbbVie
Bausch Health
Abbott
Sanofi
Sun Pharma
Endo
Apotex
Amneal Pharma
Torrent Pharma
Segment by Type
HIV
Influenza
TB
Malaria
Hepatitis
HPV
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Communicable Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Communicable Diseases Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 HIV
1.2.3 Influenza
1.2.4 TB
1.2.5 Malaria
1.2.6 Hepatitis
1.2.7 HPV
1.3 Market by Application
1.3.1 Global Communicable Diseases Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Communicable Diseases Drugs Market Perspective (2019-2030)
2.2 Communicable Diseases Drugs Growth Trends by Region
2.2.1 Global Communicable Diseases Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Communicable Diseases Drugs Historic Market Size by Region (2019-2024)
2.2.3 Communicable Diseases Drugs Forecasted Market Size by Region (2025-2030)
2.3 Communicable Diseases Drugs Market Dynamics
2.3.1 Communicable Diseases Drugs Industry Trends
2.3.2 Communicable Diseases Drugs Market Drivers
2.3.3 Communicable Diseases Drugs Market Challenges
2.3.4 Communicable Diseases Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Communicable Diseases Drugs Players by Revenue
3.1.1 Global Top Communicable Diseases Drugs Players by Revenue (2019-2024)
3.1.2 Global Communicable Diseases Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Communicable Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Communicable Diseases Drugs Revenue
3.4 Global Communicable Diseases Drugs Market Concentration Ratio
3.4.1 Global Communicable Diseases Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Communicable Diseases Drugs Revenue in 2023
3.5 Communicable Diseases Drugs Key Players Head office and Area Served
3.6 Key Players Communicable Diseases Drugs Product Solution and Service
3.7 Date of Enter into Communicable Diseases Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Communicable Diseases Drugs Breakdown Data by Type
4.1 Global Communicable Diseases Drugs Historic Market Size by Type (2019-2024)
4.2 Global Communicable Diseases Drugs Forecasted Market Size by Type (2025-2030)
5 Communicable Diseases Drugs Breakdown Data by Application
5.1 Global Communicable Diseases Drugs Historic Market Size by Application (2019-2024)
5.2 Global Communicable Diseases Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Communicable Diseases Drugs Market Size (2019-2030)
6.2 North America Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Communicable Diseases Drugs Market Size by Country (2019-2024)
6.4 North America Communicable Diseases Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Communicable Diseases Drugs Market Size (2019-2030)
7.2 Europe Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Communicable Diseases Drugs Market Size by Country (2019-2024)
7.4 Europe Communicable Diseases Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Communicable Diseases Drugs Market Size (2019-2030)
8.2 Asia-Pacific Communicable Diseases Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Communicable Diseases Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Communicable Diseases Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Communicable Diseases Drugs Market Size (2019-2030)
9.2 Latin America Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Communicable Diseases Drugs Market Size by Country (2019-2024)
9.4 Latin America Communicable Diseases Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Communicable Diseases Drugs Market Size (2019-2030)
10.2 Middle East & Africa Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Communicable Diseases Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Communicable Diseases Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Communicable Diseases Drugs Introduction
11.1.4 Novartis Revenue in Communicable Diseases Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Gilead
11.2.1 Gilead Company Detail
11.2.2 Gilead Business Overview
11.2.3 Gilead Communicable Diseases Drugs Introduction
11.2.4 Gilead Revenue in Communicable Diseases Drugs Business (2019-2024)
11.2.5 Gilead Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Communicable Diseases Drugs Introduction
11.3.4 GSK Revenue in Communicable Diseases Drugs Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Communicable Diseases Drugs Introduction
11.4.4 Roche Revenue in Communicable Diseases Drugs Business (2019-2024)
11.4.5 Roche Recent Development
11.5 Merck
11.5.1 Merck Company Detail
11.5.2 Merck Business Overview
11.5.3 Merck Communicable Diseases Drugs Introduction
11.5.4 Merck Revenue in Communicable Diseases Drugs Business (2019-2024)
11.5.5 Merck Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Communicable Diseases Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Communicable Diseases Drugs Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Communicable Diseases Drugs Introduction
11.7.4 Eli Lilly Revenue in Communicable Diseases Drugs Business (2019-2024)
11.7.5 Eli Lilly Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Communicable Diseases Drugs Introduction
11.8.4 AstraZeneca Revenue in Communicable Diseases Drugs Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 J & J
11.9.1 J & J Company Detail
11.9.2 J & J Business Overview
11.9.3 J & J Communicable Diseases Drugs Introduction
11.9.4 J & J Revenue in Communicable Diseases Drugs Business (2019-2024)
11.9.5 J & J Recent Development
11.10 Teva
11.10.1 Teva Company Detail
11.10.2 Teva Business Overview
11.10.3 Teva Communicable Diseases Drugs Introduction
11.10.4 Teva Revenue in Communicable Diseases Drugs Business (2019-2024)
11.10.5 Teva Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Communicable Diseases Drugs Introduction
11.11.4 AbbVie Revenue in Communicable Diseases Drugs Business (2019-2024)
11.11.5 AbbVie Recent Development
11.12 Bausch Health
11.12.1 Bausch Health Company Detail
11.12.2 Bausch Health Business Overview
11.12.3 Bausch Health Communicable Diseases Drugs Introduction
11.12.4 Bausch Health Revenue in Communicable Diseases Drugs Business (2019-2024)
11.12.5 Bausch Health Recent Development
11.13 Abbott
11.13.1 Abbott Company Detail
11.13.2 Abbott Business Overview
11.13.3 Abbott Communicable Diseases Drugs Introduction
11.13.4 Abbott Revenue in Communicable Diseases Drugs Business (2019-2024)
11.13.5 Abbott Recent Development
11.14 Sanofi
11.14.1 Sanofi Company Detail
11.14.2 Sanofi Business Overview
11.14.3 Sanofi Communicable Diseases Drugs Introduction
11.14.4 Sanofi Revenue in Communicable Diseases Drugs Business (2019-2024)
11.14.5 Sanofi Recent Development
11.15 Sun Pharma
11.15.1 Sun Pharma Company Detail
11.15.2 Sun Pharma Business Overview
11.15.3 Sun Pharma Communicable Diseases Drugs Introduction
11.15.4 Sun Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)
11.15.5 Sun Pharma Recent Development
11.16 Endo
11.16.1 Endo Company Detail
11.16.2 Endo Business Overview
11.16.3 Endo Communicable Diseases Drugs Introduction
11.16.4 Endo Revenue in Communicable Diseases Drugs Business (2019-2024)
11.16.5 Endo Recent Development
11.17 Apotex
11.17.1 Apotex Company Detail
11.17.2 Apotex Business Overview
11.17.3 Apotex Communicable Diseases Drugs Introduction
11.17.4 Apotex Revenue in Communicable Diseases Drugs Business (2019-2024)
11.17.5 Apotex Recent Development
11.18 Amneal Pharma
11.18.1 Amneal Pharma Company Detail
11.18.2 Amneal Pharma Business Overview
11.18.3 Amneal Pharma Communicable Diseases Drugs Introduction
11.18.4 Amneal Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)
11.18.5 Amneal Pharma Recent Development
11.19 Torrent Pharma
11.19.1 Torrent Pharma Company Detail
11.19.2 Torrent Pharma Business Overview
11.19.3 Torrent Pharma Communicable Diseases Drugs Introduction
11.19.4 Torrent Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)
11.19.5 Torrent Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
